innovative drug delivery solutionss2.q4cdn.com › ... › 2016 › intelgenx_may-20_2016.pdf ·...
TRANSCRIPT
0
Investor Presentation
May 20, 2016
Innovative Drug Delivery Solutions
1
2
To the extent any statements made in this presentation contain information that is not historical, these statements are
forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements
on our current expectations and projections about future events. Our actual results could differ materially from those
discussed in, or implied by, these forward-looking statements.
Forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "will,"
"may" and other similar expressions. In addition, any statements that refer to expectations, projections or other
characterizations of future events or circumstances are forward-looking statements. Forward-looking statements
include, but are not necessarily limited to, risks and uncertainties, including the difficulty of predicting U.S. Food and
Drug Administration and Canadian Therapeutic Products Directorate approvals, acceptance and demand for new
pharmaceutical products, the impact of competitive products and pricing, new product development and launch,
reliance on key strategic alliances, availability of raw materials and finished products, the regulatory environment, tax
rate assumptions, the outcome of legal proceedings, fluctuations in operating results and other risks detailed from
time to time in the Company's filings with the Securities and Exchange Commission and the Ontario Securities
Commission. IntelGenx undertakes no obligation to update or revise any forward-looking statement.
1
Forward Looking Statements
2
2
2
Oral Thin Films
Oral Thin Films Provide
Significant Market Opportunities
for Improving Drug Delivery
• IntelGenx CEO co-developer of the
Listerine breath strips
• Oral films ideal for elderly, children,
patients who have difficulty swallowing
traditional tablets
• Quicker action to relieve symptoms
3
3
Making Approved Drugs Better
Rapidly disintegrating film improving
drug performance and easing administration
without the need for water
Films
VersaFilm™
TabletsControlled-release tablets for oral
absorption over an extended time period
IntelGenx Drug Delivery Technology Platforms
VersaTab™ AdVersa™
4
4
Investment Highlights
VersaTab™
$1.7B TAM
• Developing proprietary
oral drug delivery technologies to address
significant market potential
• Market momentum with Forfivo XL® tablets
• Achieved first European marketing approval
of RIZAPORT™ for Migraines
• Robust product pipeline to enable expansion
into other market segments
• Achieved record 2015 revenue and
profitability
VersaFilm™
$17B TAM
5
IndicationPartnering
Availability
Formulation
Development
Pilot
StudyPivotal Study Filing Launch
Films Migraine – Rizaport TM - Rizatriptan Available ex- ES
Erectile Dysfunction - Tadalafil Available
Opioid Dependence Par
Pharmaceuticals
Schizophrenia - Loxapine Available
Undisclosed Term Sheet
Pain Term Sheet
Central Nervous System Term Sheet
Central Nervous System Available
Respiratory (Cough & Cold) In Discussion
Cardiovascular In Discussion
Tablets Major Depressive Disorder –
Forfivo XL®
Bupropion
Edgemont
Pharmaceuticals
Available ex-USA
Hypertension - Metoprolol Available
Pain - Dronabinol Available
A Robust Product Pipeline to AddressSignificant Market Opportunities
5
6
Forfivo XL
6
• High dose version of Wellbutrin XL®
• Only approved, once-daily, bupropion
HCl 450mg dose in a single tablet
• Launched commercially October 2013
in partnership with Edgemont
Pharmaceuticals
• Q1 2016 net sales grew 39% compared
to Q1 2015, with net sales at $2.5 million
($4.9 million gross)
First 450mg tablet approved by FDA for major depressive disorder
$0.00
$500.00
$1,000.00
$1,500.00
$2,000.00
$2,500.00
$3,000.00
$3,500.00
1Q15 2Q15 3Q15 4Q15 1Q16
Forfivo XL Net Sales ($,000s)
7
7
Over $17B Market Opportunity and Growth Platform for IGX
VersaFilmTM
Oral Thin Film Drug Delivery Technology
Benefits of VersaFilm™
• Improves patients compliance who have
problems swallowing tablets and capsules
to more easily take medication
• Rapid disintegration without the need for water
• Improves absorption – faster onset of action
• Potential for reduced adverse effects
$17B Addressable Market
• Successful pivotal bioequivalence studies
• Two film products awaiting FDA approval
• Limited number of competitors
MIGRAINE
Targeted
Rizatriptan Market
$2B
ERECTILE
DYSFUNCTION
Targeted
Cialis® Sales
$4.2B
OPIOID
DEPENDENCE
Targeted
Suboxone Sales
$1.7B
SCHIZOPHRENIA
Targeted
Loxapine Sales
$5.2B
8
8
For Migraines
Leverages VersaFilm™ Technology
• European Mktg Approval – November 2015
• Filed 505(b)(2) NDA - March 2013 for USA
• Co-development partnership with
RedHill Biopharma
• Negotiations with commercialization partner ongoing
• Patent granted in April 2016 protecting Rizaport
• Term Sheet signed March 2016 with
Grupo Juste for Spain & additional territories
• Planned USA submission to FDA Q4/2016
• Expected USA launch Q2/2017
9
For Erectile Dysfunction
• The first oral thin film using IntelGenx
proprietary drug delivery technology,
VersaFilm™, for ED
• Containing tadalafil (Cialis® - Eli Lilly),
a major molecule in the ED market
• Demonstrated bioequivalence to Cialis®
• Orally disintegrating films without need
for water provide unprecedented patient
convenience and a discrete dosing
alternative
• 505(b)(2) USA NDA submission in
Q4/2016
• Expected USA launch Q4/2017
9
10
For Schizophrenia & Bipolar 1 Disorder
10
• The first oral thin film using IntelGenx
proprietary drug delivery technology,
VersaFilm™, for Schizophrenia & Bipolar
1 Disorder
• Fast-acting Loxapine oral dosage – to
treat acute agitation with Schizophrenia &
Bipolar 1 Disorder in non-institutionalized
patients
• Reduces risk of pulmonary problems
and potential risk of violence and injury to
patients and others
11
Strategy Update
11
12
Strengthened Management TeamOver 20 Employees, including 7 with Ph.D.’s
Andre Godin, CPA, CA
Executive VP, CFO
• 25+ years biotech/pharma
industry experience
• Member of the Canadian
Chartered Professional
Accountants and the
Canadian Institute of
Chartered Accountants
Nadine Paiement, M. Sc.
VP, Research & Development
• Co-inventor of IntelGenx
Trilayer Technology
• 15 years experience in product
development and technology
transfer
Robert Bechard, M. Sc.
VP, Corporate Development
• 20+ years experience in
biopharmaceutical and
venture capital
• Managing Partner of
Lifescience venture fund at
RBC Capital
• Director on 25 lifescience
boards
Edward Miller, B. Comm
Director, Investor Relations
• 15 years experience in investor
relations
• 10 + years experience in
pharmaceutical / biotech
Horst G. Zerbe, Ph. D.
Chairman, President & CEO
• Co-Founder of Listerine
breath strips
• 30+ years drug delivery /
pharma experience
• Holds over 40 patents in drug
delivery and numerous
scientific publications
12
Dana Matzen, Ph.D.
VP, Business Development
• 15 years experience in
pharmaceutical product
licensing
• Former Director,
BD at Paladin Labs
• Completed 13 transaction,
7 new product launches
John Durham, B. Sc.
VP, Operations
• 20+ years experience in
pharmaceutical
manufacturing, quality
management, product
development
• Held executive positions with
several Canadian and US
companies
13
13
Completion of Constructionof Manufacturing Facility
• 17,000 sq ft facility in Montreal -
construction completed in Q1 2016
• Facility to be fully operational by Q1 2017
• High capacity manufacturing and
packaging equipment
• Lower costs, controls quality
and de-risks investment
for new products
We have built a state-of-the-art
oral film development and manufacturing facility
14
14
Strong Demographics for Oral Films
Many patient applications are compatible
with oral film characteristics
• Those who have difficult swallowing large pills:
pediatric, geriatric, or dysphagic
• North Americans over 65 will grow from 54MM to 85MM
over the next 15 years
• Patients who suffer gastrointestinal side effects
from their medication
• Normal patients who would prefer a more discrete
or pleasant administration of the drug
15
15
We are Now Poised for Success
We are focused on areas where oral films
are particularly well-suited:
• Develop and commercialize products that provide tangible patient benefits
leveraging oral films, such as:
• Reduced side effects
• Improved bio-availability
• Response time versus existing drugs
• First-to-file generic drug where high technology barriers to
entry exist in reproducing branded films
• Repurpose existing drugs for new indications using oral films
• Lifecycle management
16
Financial Results
16
17
Record Results in 2015 Demonstrates Strong Execution of Strategy
Revenue ($M)
0.820.63
5.1
1.7
0
1
2
3
4
5
6
Q1 2016 Q1 2015 2015 Full Year 2014 Full Year
Revenue
$M
17
18
Net Comprehensive Income & Adjusted EBITDA ($M)
-0.71
-0.38
0.8
-2.2
-0.56
0.05
1.7
-1.6
-2.5
-2
-1.5
-1
-0.5
0
0.5
1
1.5
2
Q1 2016 Q1 2015 2015 Full Year 2014 Full Year
Net Income Adjusted EBITDA
$M
Transforming IntelGenx for a Strong Future
18
19
Conclusion
19
20
20
Solid Platform for Growth
Significant Market Potential
• New manufacturing facility will offer many competitive advantages
• Strengthened management team to accelerate execution of business plan
• Implemented product sourcing strategy to identify high-value product opportunities
• Building strategic partnerships with relevant partners in the pharmaceutical industry
21
21
Thank You
www.IntelGenx.com